1. Generics Bulletin
  2. >>Products

Padagis Introduces Fresh Narcan Rival In US

Launches Second Naloxone Generic Alongside Adapalene Gel And Betamethasone Ointment

 
• By Dave Wallace

Padagis has added fresh competition on Narcan in the US, with its nasal naloxone spray introduced to the market as part of a trio of launches that also includes adapalene gel and betamethasone ointment.

Video Game Pixel Art Two Players
The Padagis launch represents the second US generic version of Narcan • Source: chuckchee

Padagis, the former Perrigo ‘Rx’ prescription pharmaceuticals business that was acquired by Altaris Capital Partners a year ago, has announced a trio of new launches that includes only the second US generic rival to Emergent BioSolutions’ Narcan (naloxone) 4mg nasal spray.

According to the US Food and Drug Administration’s database of approved drugs, Padagis holds one of only two US

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.